Cancer papers

Multiple myeloma research papers

Papers tagged to Multiple myeloma. Adjust filters if you want a narrower scope.

Cancer family

Cancer type

Subtype

Topic

Modality

Study type

Source

Peer-reviewed

Date from

Date to

Sort

Min rating

4 papersSorted by most recent

Time to haematologist visit and non-haematological referral from primary health care during blood cancer diagnosis - findings from a large national survey in Australia.

BMC cancer • 2026-02-17 • DOI: 10.1186/s12885-026-15757-1

Peer-reviewedImpact 61

Topics

Diagnosis

Modality

Not listed

Study type

Not listed

Abstract

Abstract not available.

Authors

Mohammad Radwanur Talukder, Emily Kovacev, Bill Stavreski, Sarah DeLacey

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify with the primary paper.

Primary source: PubMed.

Clofazimine treatment modulates key non-coding RNAs associated with tumor progression and drug resistance in lethal Prostate Cancer

pharmacology and therapeutics • 2025-02-25 • DOI: 10.1101/2025.02.20.25322381

PreprintImpact 40

Topics

Treatment, Screening / Early detection, Biology / Mechanism, Prevention / Risk

Modality

Targeted therapy, Biomarker / Liquid biopsy, Imaging

Study type

Lab / Preclinical

Abstract

Prostate cancer (PCa) is the most commonly diagnosed cancer and the second-leading cause of cancer death among men in the United States, representing 24.3% of all new cancer cases in the US. Metastatic castration-resistant prostate cancer (mCRPC) is a clinically advanced form of PCa…

Authors

Batten, S., Kumar, H., Mazumder, S., Mitra Ghosh, T. +1

AI-generated summary

Clofazimine treatment modulates key non-coding RNAs associated with tumor progression and drug resistance in lethal Prostate Cancer reports: Prostate cancer (PCa) is the most commonly diagnosed cancer and the second-leading cause of cancer death among men in the United States, representing 24.3% of all new cancer cases in the US. Metastatic castration-resistant prostate cancer (mCRPC) is a clinically advanced form of PCa that is associated with increased aggressiveness, cancer stemness, morbidity, and the risk of developing resistance to taxanes, currently the first-line chemotherapeutic agents for mCRPC.Development of new target-directed drugs to treat mCRPC poses significant challenges, given the recognition that monospecific inhibitors have limited efficacy. Hence, there is an urgent medical need to develop new strategies that block major oncogenic signaling pathways driving the most lethal forms of PCa. This is a preprint and not peer reviewed.

This summary may be inaccurate. Verify with the primary paper.

Primary source: medRxiv (not peer reviewed).

Cancer and Post-therapy Cardiotoxicity Risk in Adolescents, Young Adults, and Adults with Down Syndrome

oncology • 2025-02-23 • DOI: 10.1101/2025.02.21.25322697 • Published in 10.1002/cph4.70037

PreprintImpact 59

Topics

Treatment, Screening / Early detection, Outcomes / Survival, Side effects / Toxicity, Prevention / Risk, Epidemiology

Modality

Imaging

Study type

Observational, Review / Meta-analysis

Abstract

The median life expectancy of people with Down syndrome has increased substantially over the past several decades, from 4 years in 1970 to 53 years in 2010. Despite the recent improvement in survival, there is little data about the prevalence of age-related diseases, including…

Authors

Buckman, M., Vasileva, A., Jedlicka, C., Vasilyev, M. +4

AI-generated summary

Cancer and Post-therapy Cardiotoxicity Risk in Adolescents, Young Adults, and Adults with Down Syndrome reports: The median life expectancy of people with Down syndrome has increased substantially over the past several decades, from 4 years in 1970 to 53 years in 2010. Despite the recent improvement in survival, there is little data about the prevalence of age-related diseases, including age-related malignancies, and the impact of standard cancer treatments on cardiovascular health. We retrospectively reviewed medical records for age- and sex-matched patients [≥]15 years old with and without Down syndrome using the TriNetX platform to identify the prevalence of malignancies and explore cardiovascular outcomes after treatment with anthracyclines. This is a preprint and not peer reviewed.

This summary may be inaccurate. Verify with the primary paper.

Primary source: medRxiv (not peer reviewed).

Analysis of Multiple Myeloma Drug Efficacy

oncology • 2025-02-19 • DOI: 10.1101/2024.08.03.24311450

PreprintImpact 38

Topics

Treatment, Diagnosis, Biology / Mechanism

Modality

Imaging

Study type

Not listed

Abstract

IntroductionMultiple myeloma (MM) is an incurable plasma cell neoplasm. MM-specific alterations in methylation status cause gradual epigenetic changes and lead to pre-MM disease states, such as Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering MM (SMM). The communication between MM cells and the bone…

Authors

Matov, A.

AI-generated summary

Analysis of Multiple Myeloma Drug Efficacy reports: IntroductionMultiple myeloma (MM) is an incurable plasma cell neoplasm. MM-specific alterations in methylation status cause gradual epigenetic changes and lead to pre-MM disease states, such as Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering MM (SMM). The communication between MM cells and the bone marrow (BM) stromal cells serves a pivotal role in MM development by supporting transformed cell growth and proliferation. This is a preprint and not peer reviewed.

This summary may be inaccurate. Verify with the primary paper.

Primary source: medRxiv (not peer reviewed).